OptiNose (STU:0OP) Momentum Rank : 0 (As of May. 30, 2024)

View and export this data going back to 2024. Start your Free Trial

What is OptiNose Momentum Rank?

OptiNose has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

OptiNose Momentum Rank Related Terms

Thank you for viewing the detailed overview of OptiNose's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose (STU:0OP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (STU:0OP) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

OPTN:USA 0OP:Germany

Address

1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067

Website

https://www.optinose.com

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

OptiNose (STU:0OP) Headlines

No Headlines